NIFTY NINE IN NINETY NINE PLUS ONE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Abuckatatime who wrote (179)	1/19/1999 9:46:00 PM
From: Mike McFarland	Read Replies (1) of 613

I've seen quite a few positive sounding posts from the various biotech fellows over on threads such as VD's model portfolio etc regarding Sugen...if you're looking for a biotech in phase III trials with a vaccine, then how about BIOMF? Cell Therapeutics is really the only biotech in my portfolio right now which leans toward focusing on cancer therapies...the company licensed the worldwide rights to a class of compounds called aryl cyclams, which are anti-angiogenesis small molecules. I used to own Repligen and Magainin for anti-angiogeneseis, but settled on ctic for some exposure to that...but mainly I bought since they also have a GvHD drug in phase III, should hear about that one way or the other soon. CTIC also has a water soluble form of Taxol...but I think I already stated that when I first posted my picks here. Finally, ctic is also doing early work with a compound for treating prostate cancer --for those patients which have not responded to conventional therapy. Oh they also will be reporting on AML PIII results, and an acute lung injury drug. cticseattle.com I think Scott and I agree on this one:-) here is an earlier post techstocks.com --eom

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next